US › Healthcare

ProPhase Labs Inc (PRPH)

US · Healthcare · Diagnostics & Research

$0.02-9.47%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$1.0M

Revenue YoY

-18.9%

Net profit

$-3.1M

EPS

$0.00

EPS estimate

$-0.12

Net margin

-301.8%

EPS came in at 0.00 against a street estimate of -0.12 — a beat of 100.0%.

Key statistics

Market cap

$235,447

Forward P/E

10.5

P/B

0.37

Book value

$-0.04

EPS (TTM)

$-0.99

52-week high

$6.66

52-week low

$0.02

50-day MA

$0.05

200-day MA

$0.27

Beta

0.07

Analyst view

Analysts rate ProPhase Labs Inc a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $13.80.

Shareholding

Insiders

2.13%

Institutions

0.06%

Largest institutional holders

Fund	Stake
CoreCap Advisors, LLC	0.00%
BlackRock Inc	0.00%
Jane Street Group LLC	0.00%
Wells Fargo & Co	0.00%
Tower Research Capital LLC	0.00%
HighTower Advisors, LLC	0.00%
SIMPLEX TRADING, LLC	0.00%
UBS Group AG	0.00%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for ProPhase Labs Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.